Clinical trials: Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin
The research study is testing the investigational drug necitumumab in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy…
- Trial name
- INSPIRE (NCT00982111)
- Testing
- Pemetrexed, Cisplatin, Necitumumab
- Where
- 101 sites in United States, Australia and 18 more
- Volunteers
- 633 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer Metastatic
Registry of Guardant360® Use and Outcomes In People With Advanced Cancer
The purpose of this registry is to collect data that describes the characteristics of people with advanced cancer for whom the Guardant360 assay is ordered and to observe their clinical outcomes after receiving their results.
- Trial name
- GEODE (NCT03477474)
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Guardant Health, Inc.
Carcinoma, Non-Small-Cell Lung
A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
The primary purpose of this study is to compare the efficacy of the study drug LY2875358, given together with erlotinib, against erlotinib, alone.
- Trial name
- Balise (NCT01897480)
- Testing
- LY2875358, Erlotinib
- Where
- 45 sites in Denmark, France and 7 more
- Volunteers
- 168 people
- Sponsor
- Eli Lilly and Company
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
Non-small Cell Lung Cancer
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.
This is a retrospective, observational study of treatment patterns and clinical outcomes in Australian EGFRm advanced and metastatic non-small cell lung cancer patients treated with first-line osimertinib or second-line…
- Trial name
- NCT07213076
- Where
- Australia
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Lung Cancer
VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003847
- Testing
- biricodar dicitrate, doxorubicin hydrochloride, vincristine sulfate
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
Non Small Cell Lung Cancer
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
- Trial name
- NCT00434174
- Testing
- Everolimus, Pemetrexed
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Cutaneous Melanoma, Pleural Mesothelioma
A Study of SGN-CD228A in Advanced Solid Tumors
This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts.
- Conditions
- Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer
- Trial name
- NCT04042480
- Testing
- SGN-CD228A
- Where
- 14 sites in United States, France and 3 more
- Volunteers
- 88 people
- Sponsor
- Seagen Inc.
Non-Small Cell Lung Cancer (NSCLC)
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the efficacy and safety of tislelizumab in combination with sitravatinib compared to docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT04921358
- Testing
- Tislelizumab, Docetaxel, Sitravatinib
- Where
- 61 sites in Australia, China
- Volunteers
- 377 people
- Sponsor
- BeiGene
Carcinoma, Non-Small-Cell Lung
Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC
This is a multi-center, open-label, nonrandomized, dose-escalation, Phase 1b study of carotuximab in combination with standard dose nivolumab in patients with NSCLC that has progressed on or after platinum-based chemotherapy or…
- Trial name
- NCT03181308
- Testing
- Carotuximab (TRC105), OPDIVO
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
- Trial name
- NCT05048797
- Testing
- Trastuzumab Deruxtecan, Cisplatin, Carboplatin
- Where
- 130 sites in United States, Austria and 18 more
- Volunteers
- 454 people
- Sponsor
- AstraZeneca
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
The purpose of study is to evaluate the safety, pharmacokinetics and anti-tumor effects of CKD-702 as a monotherapy and to determine the Recommended Phase 2 Dose(RP2D) in patients with advanced or metastatic non-small cell lung…
- Trial name
- CKD-702 (NCT04667975)
- Testing
- CKD-702
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Small Cell Lung Cancer
Mass Balance Study of [14C]Chiauranib
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
- Trial name
- NCT05371899
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Solid Tumor (Phase I), Ovarian Cancer
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT07894874
- Testing
- YF550
- Volunteers
- 204 people
- Sponsor
- InventisBio Yiqi Beijing Limited
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with…
- Conditions
- Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
- Trial name
- NCT07154290
- Testing
- Ubamatamab, Marlotamig, Sarilumab
- Where
- 18 sites in United States
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Non-Small Cell Lung Cancer, Non-squamous Non-Small Cell Lung Cancer
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen
The purpose of this study is to provide treatment with nivolumab, a fully human monoclonal antibody, to subjects who have relapsed after treatment with a minimum of 1 prior systemic treatment for advanced or metastatic squamous…
- Trial name
- CheckMate 169 (NCT02475382)
- Testing
- Nivolumab
- Where
- 50 sites in Brazil, Canada
- Sponsor
- Bristol-Myers Squibb
1-5 Brain Metastases From Non-Small Cell Lung Cancer
Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)
The study is a prospective, randomly controlled phase II trial, designed to test the efficacy, safety and neurocognitive outcomes of a medical device, the NovoTTF-100A, in the treatment of NSCLC patients with controlled systemic…
- Trial name
- NCT01755624
- Testing
- NovoTTF-100A device, Best Standard of Care
- Where
- 7 sites in Czechia, France and 3 more
- Volunteers
- 18 people
- Sponsor
- NovoCure Ltd.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies
It is a Phase 1 Multicenter Open-Label Multi-Cohort Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GNR-051 in Subjects with Advanced Solid Malignancies.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma
- Trial name
- NCT04544748
- Testing
- GNR-051
- Where
- 12 sites in Russia
- Volunteers
- 48 people
- Sponsor
- AO GENERIUM
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.